Microbiome Therapeutics Market By Type (Fecal Microbial Transplant [FMT], Drugs) By Application (C. difficile, Crohn's Disease, Inflammatory Bowel Disease [IBD], Diabetes), By Region, And Segment Forecasts, 2014 - 2025

Published: Dec, 2016 | Pages: 80 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The microbiome therapeutics market is expected to reach USD 433.5 million by 2025, based on a new study by Grand View Research, Inc. Increasing funding initiatives and government programs to support this research are high impact rendering drivers anticipated to foster market growth.

The launch of Human Microbiome Project by NHS in Europe and the Microbiome Initiative by the U.S. government are some of the crucial government initiatives pertaining to market growth. The U.S. government has announced to have invested over USD 121 million in the Microbiome Initiative with additional USD 100 million from the Bill and Melinda Gates Foundation.

Presence of strong drug pipeline can also be attributed to the highly lucrative growth. Key players are entering into collaborative agreements with venture capital firms and research institutes for enhancing therapeutics pipeline through development of efficient and safe drugs. Some of the companies that recently formed collaborative agreements are Seventure Partners & ENTEROME Bioscience; Vedanta Biosciences & Johnson & Johnson Pvt. Ltd.; and Seventure Partners & Eligo Bioscience.

Further Key Findings from the Study Suggest:

•	Fecal Microbial Transplant (FMT) held the largest market share in 2015 owing to easier availability and introduction of FMT capsules by Open Biome

•	Introduction of RBX2660, a phase 3 molecule, during the end of 2018 will result in substantial increase in revenue of FMT

•	No commercial microbiome drugs are currently available with FMT being the only therapy for treatment. Drugs are estimated to hit the market by fourth quarter of 2017.

•	It is estimated that the drugs segment would witness the fastest growth owing to the presence of blockbuster drugs, such as, NM504, SER-109, RP-G28, and SGM-1019, in the pipeline

•	C. difficile dominated the application segment in 2015 with Crohn's disease leading the market CAGR over the forecast period

•	North America held the largest share in 2015, owing to presence of major companies & established healthcare infrastructure and high amount of research activities

•	Asia Pacific is anticipated to witness significant growth with increasing acceptance of FMT in developing countries, such as India and China

•	Some of the key companies are MicroBiome Therapeutics, LLC; Seres Therapeutics; ENTEROME Bioscience; MaaT Pharma; Rebiotix, Inc.; Ritter Pharmaceuticals; Second Genome, Inc.; and OpenBiome

•	High investment on research and development of new drugs and investigation of available drugs for more untapped applications are the main strategies undertaken by the key players

 Table of Contents

Chapter 1 Research Methodology & Scope
                     1.1 Information Procurement
                        1.1.1 Purchased database:
                        1.1.2 GVR's internal database
                     1.2 Research Methodology
                     1.3 Geographic scope & assumptions
                     1.4 Region-wise market calculation
                        1.4.1 Region-wise market: Base estimates
                        1.4.2 Global market: CAGR calculation
                     1.5 Region-based segment share calculation
                     1.6 List of Secondary Sources

Chapter 2 Executive Summary
                     2.1 Market Snapshot

Chapter 3 Microbiome Market Variables, Trends & Scope
                     3.1 Market segmentation& scope
                        3.1.1 Market Driver Analysis
                              3.1.1.1 Increasing base of target population
                              3.1.1.2 Increasing research funding
                              3.1.1.3 Rising awareness
                              3.1.1.4 Strong product pipeline
                        3.1.2 Market restraint analysis
                              3.1.2.1 High cost
                     3.2 Penetration & growth prospect mapping
                     3.3 Microbiome therapeutics- SWOT Analysis, By Factor (political & legal, economic and technological)
                     3.4 Industry Analysis - Porter's
                     3.5 Product Pipeline analysis
                     3.6 Technology overview (qualitative analysis: current and future aspects)

Chapter 4 Microbiome Market: Type Estimates & Trend Analysis
                     4.1 Microbiome therapeutics market: Type movement analysis
                     4.2 Fecal Microbial Transplant (FMT)
                        4.2.1 Fecal microbial transplant market, 2014 - 2025 (USD Million)
                     4.3 Drugs
                        4.3.1 Drugs market, 2014 - 2025 (USD Million)

Chapter 5 Microbiome Market: Application Estimates & Trend Analysis
                     5.1 Microbiome therapeutics market: Application movement analysis
                     5.2 Clostridium difficle infection
                        5.2.1 C.difficle market, 2014 - 2025 (USD Million)
                     5.3 Crohns disease
                        5.3.1 Crohns disease market, 2014 - 2025 (USD Million)
                     5.4 IBD
                        5.4.1 IBD market, 2014 - 2025 (USD Million)
                     5.5 Diabetes
                        5.5.1 Diabetes market, 2014 - 2025 (USD Million)
                     5.6 Others
                        5.6.1 Others market, 2014 - 2025 (USD Million)

Chapter 6 Microbiome Market: Regional Estimates & Trend Analysis, by Application
                     6.1 Microbiome therapeutics market share by region, 2015 & 2025
                     6.2 North America
                        6.2.1 North America microbiome therapeutics market, 2014 - 2025 (USD Million)
                        6.2.2 U.S
                              6.2.2.1 U.S microbiome therapeutics market, 2014 - 2025 (USD Million)
                        6.2.3 Canada
                              6.2.3.1 Canada microbiome therapeutics market, 2014 - 2025 (USD Million)
                     6.3 Europe
                        6.3.1 Europe microbiome therapeutics market, 2014 - 2025 (USD Million)
                        6.3.2 UK
                              6.3.2.1 UK microbiome therapeutics market, 2014 - 2025 (USD Million)
                        6.3.3 Germany
                              6.3.3.1 Germany microbiome therapeutics market, 2014 - 2025 (USD Million)
                     6.4 Asia Pacific
                        6.4.1 Asia Pacific microbiome therapeutics market, 2014 - 2025 (USD Million)
                        6.4.2 Japan
                              6.4.2.1 Japan microbiome therapeutics market, 2014 - 2025 (USD Million)
                        6.4.3 China
                              6.4.3.1 China microbiome therapeutics market, 2014 - 2025 (USD Million)
                        6.4.4 India
                              6.4.4.1 India microbiome therapeutics market, 2014 - 2025 (USD Million)
                     6.5 Latin America
                        6.5.1 Latin America microbiome therapeutics market, 2014 - 2025 (USD Million)
                        6.5.2 Brazil
                              6.5.2.1 Brazil microbiome therapeutics market, 2014 - 2025 (USD Million)
                        6.5.3 Mexico
                              6.5.3.1 Mexico microbiome therapeutics market, 2014 - 2025 (USD Million)
                     6.6 MEA
                        6.6.1 MEA microbiome therapeutics market, 2014 - 2025 (USD Million)
                        6.6.2 South Africa
                              6.6.2.1 South Africa microbiome therapeutics market, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape
                     7.1 Strategy Framework
                     7.2 Market Participation Categorization
                     7.3 Company Profiles
                        7.3.1 MicroBiome Therapeutics LLC
                              7.3.1.1 Company overview
                              7.3.1.2 Financial performance
                              7.3.1.3 Product benchmarking
                              7.3.1.5 Strategic initiatives
                        7.3.2 Seres Therapeutics
                              7.3.2.1 Company overview
                              7.3.2.2 Financial performance
                              7.3.2.3 Product benchmarking
                              7.3.2.4 Strategic initiatives
                        7.3.3 Enterome Bioscience
                              7.3.3.1 Company overview
                              7.3.3.2 Financial performance
                              7.3.3.3 Product benchmarking
                              7.3.3.4 Strategic initiatives
                        7.3.4 MaaT Pharma
                              7.3.4.1 Company overview
                              7.3.4.2 Financial performance
                              7.3.4.3 Product benchmarking
                              7.3.4.4 Strategic initiatives
                        7.3.5 Rebiotix, Inc
                              7.3.5.1 Company overview
                              7.3.5.2 Financial performance
                              7.3.5.3 Product benchmarking
                              7.3.5.4 Strategic initiatives
                        7.3.6 Ritter Pharmaceuticals
                              7.3.6.1 Company overview
                              7.3.6.2 Financial performance
                              7.3.6.3 Product benchmarking
                              7.3.6.4 Strategic initiatives
                        7.3.7 Second Genome
                              7.3.7.1 Company overview
                              7.3.7.2 Financial performance
                              7.3.7.3 Product benchmarking
                              7.3.7.4 Strategic initiatives
                        7.3.8 OpenBiome
                              7.3.8.1 Company overview
                              7.3.8.2 Financial performance
                              7.3.8.3 Product benchmarking
                              7.3.8.4 Strategic initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 North America microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 3 North America microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 4 U.S. microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 5 U.S. microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 6 Canada microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 7 Canada microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 8 Europe microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 9 Europe microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 10 UK microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 11 UK microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 12 Germany microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 13 Germany microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 14 Asia Pacific microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 15 Asia Pacific microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 16 Japan microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 17 Japan microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 18 China microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 19 China microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 20 India microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 21 India microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 22 Latin America microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 23 Latin America microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 24 Brazil microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 25 Brazil microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 26 Mexico microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 27 Mexico microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 28 MEA microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 29 MEA microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 30 South Africa microbiome therapeutics market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 31 South Africa microbiome therapeutics market estimates and forecasts, by application, 2014 - 2025 (USD Million)